

Performance in Delivery-Quarter 4 (2015-16)

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Number of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Reason For Closure Of Trial	Comments
14/SS/0049	143780	A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, 26-Week, Phase 3 Study of Two Doses of EVP-6124 or Placebo in Subjects with Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication	Number Agreed	8	8	Date Agreed	15/05/2016	0	19/08/2015	Withdrawn By Sponsor	suspended then closed for safety reasons
12/SC/0435	107849	Efficacy and Safety of 3 doses of S38093 (2,5 and 20mg) versus placebo in co-administration with donezepil (10mg/day) in patients with moderate Alzheimers Disease	Number Agreed	4	6	Date Agreed	01/04/2015	4	01/04/2015	Recruitment Finished	
12/ME/0410	111232	A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 in Subjects with Mild to Moderate Alzheimer's Disease	Number Agreed	3	4	Date Agreed	29/01/2016	4	08/09/2015	Recruitment Finished	